4 / 28
N=419
Time from ADT to mCRPC
- Median (range)
28.1
(24.4-31.7)
CSS from mCRPC
- Median (range)
32.7
(28.8-36.6)
Treatment for mHSPC
•aLHRH/aGnRH
•Max Androgen Blockage
•Docetaxel and aLHRH
249 (59.4%)
143 (34%)
27 6.4%)
Treatment lines for mCRPC
•Total n
o
lines
•SPT lines
3 (1-9)
2 (1-5)
Survival Prolonguing Therapies
•Abiraterone
•Enzalutamida
•Docetaxel
•Cabazitaxel
•Radium-23
302 (72.1%)
126 (30.1%)
316 (75.4%)
132 (31.5%)
69 (16.5%)
No SPT
• Ketokonazole
• Steroids
• Estrogens
• Ciclofosfamide
• Mitroxantrone
• Platium-based chemotherapy
16 (3.9%)
58 (13.8%)
14 (3.34%)
47 (11.2%)
25 (5.9%)
24 (5.7%)
Data from Spanish mCRPC patients
PROREPAIR_B study
419 mCRPC
38 centres
Jan 2013-April 2016
Data cut-off: Nov 2017
Follow-up:
40
months
253 deaths (60%)
Castro et al, manuscript in preparation